Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop Treatments for MS, Other Autoimmune Indications

By: via Benzinga
Novartis (NYSE: NVS) announced today that it has entered into an agreement to acquire all remaining rights to Ofatumumab from ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.